PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...
The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop ...
The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...
VIBRANT (NCT06164704) was a Phase 2 global, randomized, double-blind, placebo-controlled, parallel group clinical trial that evaluated the efficacy and safety of verekitug over 24 weeks in 81 adults ...
Please provide your email address to receive an email when new articles are posted on . Twelve-year data were available for 71 patients, or 85.5% of the assessed study population. Around 55% of those ...
Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations Of 336 ...
An adenomatous polyp in which malignant cells have invaded beyond the muscularis mucosa into the submucosa may still be curable by colonoscopic polypectomy under specific conditions, depending on the ...
SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for further treatments, the WAYPOINT trial showed. The monoclonal ...
On Saturday, Amgen Inc (NASDAQ:AMGN) and AstraZeneca Plc (NASDAQ:AMGN) announced full results from the Phase 3, registrational WAYPOINT trial evaluating the efficacy and safety of tezepelumab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results